We are pleased to announce that FCF has awarded Dr. Juliane Walz of the University Hospital Tübingen a grant to develop and launch a new clinical trial for FLC patients. This phase I study will assess the safety and efficacy of a peptide vaccine (Fusion-VAC-XS15) against FLC’s driver protein in a different clinical context than …
Thanks to the incredible generosity of Stone Point Capital (SPC), tournament sponsors, and participants, this year’s SPC Charity Golf Tournament raised over a million dollars to support fibrolamellar research! Over the years, this annual fundraiser has tremendously impacted FCF’s ability to fund critical research into the disease. At the event, Chuck and Marna Davis discussed …
A perspective on Rare Cancer Day. This year more than 600,000 lives in the US will be lost to cancer. The five most common malignancies account for half of these deaths. Most of the victims are elderly; fewer than 2% of cancer fatalities occur under age 40. Rarer cancers, especially those affecting youthful patients, receive …
Congratulations to Marina Baretti, MD who was installed as the inaugural recipient of the Jiasheng Professorship in Hepato-Biliary Cancer Research at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Dr. Baretti has been actively involved in both FLC patient care and research. She has been instrumental to several path breaking research efforts for this disease, …
In a study funded by FCF, scientists at Cornell University analyzed the differences in the proteins and metabolites present in fibrolamellar carcinoma (FLC) and normal tissues to better understand the metabolism of the disease. Their findings, published in Cell Reports Medicine on August 28, offer deep insights into the metabolic alterations that occur in FLC, …
A new era in cancer therapy dawned in 2011 when the FDA approved ipilimumab (Yervoy) to treat metastatic melanoma. This was the first of a novel class of drugs called immune checkpoint inhibitors (ICIs), which “take the brakes off” the immune system’s ability to kill cancer cells. Today eleven different ICIs are available in the …
Here’s your chance to double your impact on fibrolamellar research! Thanks to the generosity of the Chuck & Marna Davis family …
“You are what you eat” is a phrase popularized by the American nutritionist Victor Lindlahr in the 1930s. Of course, the body’s cells have no way to determine whether the nutrients that reach them come from a four-star gourmet meal or a hot dog on a bun. However, for years, it has been recognized that …
Virtual registration is still open for FCF’s second Fibrolamellar Patient & Research Summit to be held on Sunday, June 9 through Monday, June 10 in Greenwich, Connecticut. This summit is meant to be a collaborative working session in which fibrolamellar patients, caregivers, clinicians and researchers discuss the current state of FLC research, share perspectives, and …